Subtype
Astrocytoma
CI-CAN-00004510Explore in graph →
Non-malignant74 active trials1 approved drugs24 evidence items
Loading cancer entity…
Subtype
CI-CAN-00004510Explore in graph →
Clinical trials
362 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03796273 | Ketoconazole Before Surgery in Treating Patients With Recurrent Glioma or Breast Cancer Brain Metastases | terminated | Early Phase 1 | 15 | Wake Forest University Health SciencesOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT06333899 | Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion | recruiting | Early Phase 1 | 15 | Nationwide Children's HospitalOTHER | 6 | Jun 29, 2026 | clinicaltrials |
| NCT01165632 | Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma | completed | Early Phase 1 | 24 | Mayo ClinicOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT04135807 | Implantable Microdevice In Primary Brain Tumors | recruiting | Early Phase 1 | 12 | Oliver JonasOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT03893487 | Fimepinostat in Treating Brain Tumors in Children and Young Adults(PNOC016) | active not recruiting | Early Phase 1 | 30 | Sabine Mueller, MD, PhDOTHER | 2 | Jul 11, 2025 | clinicaltrials |
| NCT02077543 | Multicenter Safety Trial Assessing an Innovative Tumor Molecular and Cellular Print Medical Device in Glioma(ProTool) | unknown | Early Phase 1 | 150 | University Hospital, GrenobleOTHER | 1 | Mar 25, 2020 | clinicaltrials |
| NCT00795457 | Effects of Vaccinations With HLA-A2-Restricted Glioma Antigen-Peptides in Combination With Poly-ICLC for Adults With High-Risk WHO Grade II Astrocytomas and Oligo-Astrocytomas | completed | Early Phase 1 | 13 | Ian F. Pollack, M.D.OTHER | 1 | Aug 30, 2019 | clinicaltrials |
| NCT02490930 | A Safety Study of Fingolimod With Radiation and Temozolomide in Newly Diagnosed High Grade Glioma | completed | Early Phase 1 | 5 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 13, 2017 | clinicaltrials |
| NCT01996527 | 3T MRI Biomarkers of Glioma Treatment Response | terminated | Early Phase 1 | 7 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Apr 17, 2017 | clinicaltrials |
| NCT02976441 | Autologous Stem Cell Collection and Reinfusion in Newly Diagnosed High Grade Gliomas | withdrawn | Early Phase 1 | 0 | Washington University School of MedicineOTHER | 0 | Feb 20, 2017 | clinicaltrials |
| NCT00874861 | HLA-A2-Restricted Glioma Antigen-Peptides Vaccinations With Poly-ICLC for Recurrent WHO Grade II Gliomas | completed | Early Phase 1 | 10 | Ian F. Pollack, M.D.OTHER | 1 | Dec 8, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Jul 31, 2026source: clinicaltrials